Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on asymmetric C H activation. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN109970713B details novel amino acid-based Ir(III) catalysts enabling high-efficiency asymmetric C-H activation for cost-effective API manufacturing.
Patent CN117586310A reveals a novel Ni-Al bimetallic catalyst for enantioselective C(sp3)-H activation, offering cost reduction in pharmaceutical intermediates manufacturing and high-purity chiral nitrogen-containing heterocycles.
Patent CN113150031A discloses a novel oxaspiro chiral phosphoric acid enabling >97% ee in asymmetric synthesis. Reliable supplier for high-purity pharmaceutical intermediates.
Patent CN114478608A discloses Rh-catalyzed enantioselective silylation. Offers high ee values and novel structures for functional materials and pharma intermediates.
Patent CN116041207A reveals a novel chiral spiroindane ligand enabling high-selectivity C-H activation. Discover cost-effective synthesis and supply chain advantages.
Patent CN119530825B details cobalt-catalyzed electrochemical synthesis for high-purity chiral intermediates. Offers sustainable cost reduction and scalable supply chain solutions.
Patent CN109678911B details a high-efficiency Rh-catalyzed method for planar chiral ferrocene intermediates, offering superior enantioselectivity and supply chain reliability.
Patent CN116041216A reveals a high-yield Pd-catalyzed asymmetric C-H arylation method. This breakthrough offers reliable pharmaceutical intermediate suppliers a scalable route for chiral amides with superior enantioselectivity.
Novel Rh-catalyzed C-H activation method for high-purity axial chiral intermediates with superior enantioselectivity and scalable process efficiency.
Patent CN108558927B details a novel Pd-catalyzed asymmetric alkenylation for silicon stereocenters. Discover cost-effective routes for high-purity pharmaceutical intermediates.
Solve low-yield C-H activation challenges with 94% yield & 92% ee. Scale to 100MT/yr with no byproducts. Contact for COA/MSDS.